Half-year Report

AI SummaryClose X

Verici Dx plc reported half-year revenues of $1.8 million for the six months ended 30 June 2026, a decrease from $1.9 million in the prior year period, though Tutivia testing revenues increased by 53% to $1.77 million. The company experienced an adjusted EBITDA loss of $3.5 million, an increase from the $2.8 million loss in H1 2025, and its cash balance stood at $2.4 million as of 30 June 2026. Despite a net cash outflow from operating activities of $3.8 million, Verici Dx successfully completed an equity fundraise in June 2026, raising gross proceeds of £2.6 million ($3.4 million), and has announced plans for a further equity raise to support growth. Operational highlights include onboarding 32 transplant centres for Tutivia testing, with an average reimbursement rate of $2,300 per test, and Protega™ receiving an additional CPT® PLA code for commercial reimbursement.

Disclaimer*

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings